-
SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing FirstLine Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression =50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression
This study is testing two different treatments (LY3537982 in combination with pembrolizumab against a placebo combined with pembrolizumab) for a cancer called KRAS G12C-mutant NSCLC ...
-
A Phase 3 Randomized Double-blind Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II IIIA IIIB (N2) Non-small Cell Lung Cancer
This clinical study will evaluate V940 plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of completely resected (R0) Stage II to IIIB (N2 ... -
BGB-11417-301 Protocol title: A Phase 3 Open-Label Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
BGB-11417-301 Protocol title: A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated ... -
MAGNITUDE: A Phase 3 Multinational Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
This trial is recruiting patients with a condition known as Transthyretin (TTR) Amyloidosis with Cardiomyopathy or ATTR-CM. In individuals with this condition, the heart muscle ... -
A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)
A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with ... -
M20-638: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL TRIAL OF EPCORITAMAB IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE (R2) COMPARED TO RITUXIMAB AND LENALIDOMIDE (R2) ALONE IN SUBJECTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
This is a trial testing a new medicine called epcoritamab, when used with other medicines called rituximab and lenalidomide (together called "R2"), to see if ...
-
Randomized Open-label Multicenter Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-na ve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
This is a study to compare two medicines (repotrectinib and crizotinib) for patients with a type of lung cancer called ROS1-positive NSCLC (Non-small Cell Lung ...
-
A Single-Center Phase 3 Study of RELAXaHEAD: A Behavioral Approach to Remote Migraine Management in Primary Care
Migraine is the second most disabling condition worldwide. We know that it can be hard for patients to access migraine care. Thus, we are conducting ... -
A Phase III Randomized Double-Blind Placebo-Controlled Non-Inferiority Multi-Center Study of the Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
This study aims to develop evidence-based protocols for managing older patients with systemic lupus erythematosus (SLE), a topic that has been largely overlooked. Hydroxychloroquine (HCQ ... -
SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE
The purpose of this program is to assess the safety and efficacy of upadacitinib compared with placebo (fake drug) for the treatment of signs and ...